Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech Limited has submitted its financial results for the quarter and half-year ended September 30, 2025 to the stock exchange. The filing confirms compliance with SEBI's listing requirements regarding periodic disclosure of financial performance. The actual detailed numbers, including revenue, profit after tax, and segment-wise performance, are contained in the submitted results document and not reproduced in this announcement text. Investors would need to refer to the attached financial statements for a full picture of the company's Q2 FY26 performance.
Routine regulatory submission — no immediate price action expected from the filing itself. Shareholders should review the attached results for actual revenue and profit trends to gauge the company's operating performance.